Inhibitor Therapeutics, Inc.
INTI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $5,607 | $8,840 | $11,951 | $31 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $88 | $109 | $24 | $28 |
| Total Curr. Assets | $5,695 | $8,949 | $11,975 | $59 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $5,695 | $8,949 | $11,975 | $59 |
| Liabilities | – | – | – | – |
| Payables | $16 | $34 | $145 | $280 |
| Short-Term Debt | $0 | $0 | $411 | $231 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $3,000 | $116 |
| Other Curr. Liab. | $694 | $631 | $245 | $169 |
| Total Curr. Liab. | $710 | $665 | $679 | $680 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $3,000 | $3,000 | $3,000 | $3,000 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $3,000 | $3,000 | $3,000 | $3,000 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $3,710 | $3,665 | $3,679 | $3,680 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $3,961 |
| Common Stock | $17 | $17 | $17 | $38 |
| Retained Earnings | -$52,119 | -$48,780 | -$45,754 | -$57,671 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $54,087 | $54,047 | $54,033 | $50,052 |
| Total Equity | $1,985 | $5,284 | $8,296 | -$3,621 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $5,695 | $8,949 | $11,975 | $59 |
| Net Debt | -$5,607 | -$8,840 | -$11,540 | $200 |